RT Journal Article
SR Electronic
T1 Second wave of COVID-19 in India could be predicted with genomic surveillance of SARS-CoV-2 variants coupled with epidemiological data: A tool for future
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.09.21258612
DO 10.1101/2021.06.09.21258612
A1 Kumar, Ashutosh
A1 Dwivedi, Prakhar
A1 Kumar, Gopichand
A1 Narayan, Ravi K.
A1 Jha, RakeshK.
A1 Parashar, Rakesh
A1 Sahni, Chetan
A1 Pandey, Sada N.
YR 2021
UL http://medrxiv.org/content/early/2021/06/12/2021.06.09.21258612.abstract
AB India has witnessed a devastating second wave of COVID-19, which peaked during the last week of April and the second week of May, 2021. We aimed to understand whether the arrival of second wave was predictable and whether it was driven by the existing SARS-CoV-2 strains or any of the emerging variants. We analyzed the monthly distribution of the genomic sequence data for SARS-CoV-2from India and correlated that with the epidemiological data for new cases and deaths, for the corresponding period of the second wave. Our analysis shows that the first indications of arrival of the second wave were observable by January, 2021, and by March, 2021 it was clearly predictable. B.1.617 lineage variants drove the wave, particularly B.1.617.2 (a.k.a. delta variant). We propose that genomic surveillance of the SARS-CoV-2 variants augmented with epidemiological data can be a promising tool for predicting future COVID-19 waves.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available from corresponding author on reasonable request.